Ana Belén Azuaga, Andrea Cuervo, Delia Reina, Paula Estrada Alarcón, Lourdes Mateo, María Aparicio, Mireia Moreno, Marta Arévalo, Ana Láiz, Patricia Moya, Lucía Alascio, Josep Riera, José U Scher, Juan D Cañete, Julio Ramírez
{"title":"无肌肉骨骼症状的银屑病患者队列的临床和超声特征:一项前瞻性和多中心研究","authors":"Ana Belén Azuaga, Andrea Cuervo, Delia Reina, Paula Estrada Alarcón, Lourdes Mateo, María Aparicio, Mireia Moreno, Marta Arévalo, Ana Láiz, Patricia Moya, Lucía Alascio, Josep Riera, José U Scher, Juan D Cañete, Julio Ramírez","doi":"10.1093/rheumatology/keaf307","DOIUrl":null,"url":null,"abstract":"Objectives To evaluate clinical and ultrasound (US) features related to psoriatic arthritis (PsA) development in psoriasis (PsO), patients without musculoskeletal (MSK) symptoms and no systemic treatment. Methods Prospective study including PsO patients followed by dermatologists. Clinical, and US data were collected at baseline and during follow-up by rheumatologists. Results Seventy-eight patients with PsO were included. Mean disease duration was 15.1 years (SD ± 13.4); most had mild PsO (82%), onychopathy was present in 36 (39.7%) and overweight/obesity in 38 patients (48.7%). In the US evaluation, 9 patients (11.5%) had Power Doppler grade 1 at joints, 56.4% had calcifications and 30.4% bursitis at enthesis. Sixty patients completed the study. After a median of 76.60 months (IQR 39.34-85.25), 34 patients (56.6%) developed MSK symptoms. They had higher BMI (p = 0.013), abdominal circumference (p = 0.022), scored higher for pain (p = 0.047) and fatigue (p = 0.011). Their baseline US showed a higher total US score (p = 0.037). Five patients (8.3%) developed MSK inflammatory symptoms, and 4 met CASPAR criteria (5,5%). The mean time from baseline to PsA diagnosis was 20.20 months (SD ± 12.02). US bursitis was present in 80% of patients developing inflammatory symptoms (p = 0.049). Conclusions In a cohort of patients with mild PsO, systemic therapy-naïve and no MSK symptoms, incidence of PsA was 1% per year. US bursitis at enthesis was related to the development of symptoms suggestive of PsA. Patients who developed MSK symptoms had higher BMI, fatigue and pain VAS scores at baseline and could constitute a subgroup with higher risk for transition to PsA.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"42 1","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical and ultrasound features of a cohort of psoriasis patients without musculoskeletal symptoms: a prospective and multicenter study\",\"authors\":\"Ana Belén Azuaga, Andrea Cuervo, Delia Reina, Paula Estrada Alarcón, Lourdes Mateo, María Aparicio, Mireia Moreno, Marta Arévalo, Ana Láiz, Patricia Moya, Lucía Alascio, Josep Riera, José U Scher, Juan D Cañete, Julio Ramírez\",\"doi\":\"10.1093/rheumatology/keaf307\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives To evaluate clinical and ultrasound (US) features related to psoriatic arthritis (PsA) development in psoriasis (PsO), patients without musculoskeletal (MSK) symptoms and no systemic treatment. Methods Prospective study including PsO patients followed by dermatologists. Clinical, and US data were collected at baseline and during follow-up by rheumatologists. Results Seventy-eight patients with PsO were included. Mean disease duration was 15.1 years (SD ± 13.4); most had mild PsO (82%), onychopathy was present in 36 (39.7%) and overweight/obesity in 38 patients (48.7%). In the US evaluation, 9 patients (11.5%) had Power Doppler grade 1 at joints, 56.4% had calcifications and 30.4% bursitis at enthesis. Sixty patients completed the study. After a median of 76.60 months (IQR 39.34-85.25), 34 patients (56.6%) developed MSK symptoms. They had higher BMI (p = 0.013), abdominal circumference (p = 0.022), scored higher for pain (p = 0.047) and fatigue (p = 0.011). Their baseline US showed a higher total US score (p = 0.037). Five patients (8.3%) developed MSK inflammatory symptoms, and 4 met CASPAR criteria (5,5%). The mean time from baseline to PsA diagnosis was 20.20 months (SD ± 12.02). US bursitis was present in 80% of patients developing inflammatory symptoms (p = 0.049). Conclusions In a cohort of patients with mild PsO, systemic therapy-naïve and no MSK symptoms, incidence of PsA was 1% per year. US bursitis at enthesis was related to the development of symptoms suggestive of PsA. Patients who developed MSK symptoms had higher BMI, fatigue and pain VAS scores at baseline and could constitute a subgroup with higher risk for transition to PsA.\",\"PeriodicalId\":21255,\"journal\":{\"name\":\"Rheumatology\",\"volume\":\"42 1\",\"pages\":\"\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/rheumatology/keaf307\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keaf307","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Clinical and ultrasound features of a cohort of psoriasis patients without musculoskeletal symptoms: a prospective and multicenter study
Objectives To evaluate clinical and ultrasound (US) features related to psoriatic arthritis (PsA) development in psoriasis (PsO), patients without musculoskeletal (MSK) symptoms and no systemic treatment. Methods Prospective study including PsO patients followed by dermatologists. Clinical, and US data were collected at baseline and during follow-up by rheumatologists. Results Seventy-eight patients with PsO were included. Mean disease duration was 15.1 years (SD ± 13.4); most had mild PsO (82%), onychopathy was present in 36 (39.7%) and overweight/obesity in 38 patients (48.7%). In the US evaluation, 9 patients (11.5%) had Power Doppler grade 1 at joints, 56.4% had calcifications and 30.4% bursitis at enthesis. Sixty patients completed the study. After a median of 76.60 months (IQR 39.34-85.25), 34 patients (56.6%) developed MSK symptoms. They had higher BMI (p = 0.013), abdominal circumference (p = 0.022), scored higher for pain (p = 0.047) and fatigue (p = 0.011). Their baseline US showed a higher total US score (p = 0.037). Five patients (8.3%) developed MSK inflammatory symptoms, and 4 met CASPAR criteria (5,5%). The mean time from baseline to PsA diagnosis was 20.20 months (SD ± 12.02). US bursitis was present in 80% of patients developing inflammatory symptoms (p = 0.049). Conclusions In a cohort of patients with mild PsO, systemic therapy-naïve and no MSK symptoms, incidence of PsA was 1% per year. US bursitis at enthesis was related to the development of symptoms suggestive of PsA. Patients who developed MSK symptoms had higher BMI, fatigue and pain VAS scores at baseline and could constitute a subgroup with higher risk for transition to PsA.
期刊介绍:
Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press.
Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.